We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+26.71%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$624M
AUM Growth
+$131M
Cap. Flow
+$40.1M
Cap. Flow %
6.42%
Top 10 Hldgs %
81.94%
Holding
58
New
13
Increased
11
Reduced
7
Closed
13

Top Buys

Rank Stock Value
1
MOBI
Mobia Medical
MOBI
+$10.3M
2
SENS icon
Senseonics Holdings Inc
SENS
+$10.3M
3
CGON icon
CG Oncology
CGON
+$7.19M
4
ELVN icon
Enliven Therapeutics
ELVN
+$6.37M
5
JBIO
Jade Biosciences
JBIO
+$6.26M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$8.33M
2
VIR icon
Vir Biotechnology
VIR
+$4.1M
3
MDT icon
Medtronic
MDT
+$2.42M
4
CNC icon
Centene
CNC
+$2.29M
5
NTRA icon
Natera
NTRA
+$1.8M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Consumer Staples 0.17%
3 Consumer Discretionary 0.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DNTH icon
1
Dianthus Therapeutics
DNTH
$5.92B
$205M 32.85%
2,104,184
– –
CGON icon
2
CG Oncology
CGON
$6.59B
$99.4M 15.92%
1,398,948
+110,000
+9% +$7.19M
ORKA
3
Oruka Therapeutics
ORKA
$6.03B
$72.4M 11.59%
760,424
– –
JBIO
4
Jade Biosciences
JBIO
$1.33B
$37.8M 6.05%
1,700,708
+300,000
+21% +$6.26M
ELVN icon
5
Enliven Therapeutics
ELVN
$4.24B
$27.9M 4.47%
550,000
+150,000
+38% +$6.37M
CATX icon
6
Perspective Therapeutics
CATX
$355M
$21.5M 3.44%
6,299,999
+250,000
+4% +$944K
AKTS
7
Aktis Oncology
AKTS
$1.43B
$15.6M 2.5%
484,200
+15,634
+3% +$321K
PVLA
8
Palvella Therapeutics
PVLA
$2.16B
$10.7M 1.71%
70,000
– –
MOBI
9
Mobia Medical
MOBI
$378M
$10.7M 1.71%
+798,282
New +$10.3M
RGEN icon
10
Repligen
RGEN
$9.95B
$10.6M 1.7%
77,800
– –
IMUX icon
11
Immunic
IMUX
$210M
$10.3M 1.65%
669,941
– –
SENS icon
12
Senseonics Holdings Inc
SENS
$493M
$9.09M 1.46%
+1,600,000
New +$10.3M
KPTI icon
13
Karyopharm Therapeutics
KPTI
$42.4M
$9.03M 1.45%
924,487
+460,746
+99% +$4M
TEVA icon
14
Teva Pharmaceuticals
TEVA
$42.5B
$6.78M 1.09%
200,000
-250,100
-56% -$8.33M
DXCM icon
15
DexCom
DXCM
$34.3B
$6.74M 1.08%
100,000
+10,000
+11% +$666K
TEM
16
Tempus AI
TEM
$11.6B
$6.08M 0.97%
105,000
+80,000
+320% +$4.01M
MDT icon
17
Medtronic
MDT
$117B
$5.48M 0.88%
70,000
-30,000
-30% -$2.42M
VIR icon
18
Vir Biotechnology
VIR
$1.83B
$5.29M 0.85%
519,300
-430,700
-45% -$4.1M
GPCR icon
19
Structure Therapeutics
GPCR
$3.38B
$5.26M 0.84%
98,000
+68,000
+227% +$3.01M
EHC icon
20
Encompass Health
EHC
$11.9B
$4.25M 0.68%
42,000
– –
TENX icon
21
Tenax Therapeutics
TENX
$79.7M
$3.87M 0.62%
265,934
+50,000
+23% +$639K
NVCT icon
22
Nuvectis Pharma
NVCT
$775M
$3.68M 0.59%
+200,000
New +$2.24M
PODD icon
23
Insulet
PODD
$10.1B
$3.65M 0.59%
+24,000
New +$4M
BSX icon
24
Boston Scientific
BSX
$67.9B
$3.41M 0.55%
80,000
+20,000
+33% +$1.09M
MSLE
25
Satellos Bioscience
MSLE
$184M
$3.01M 0.48%
387,769
– –
1
2 3

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q2 2026 Portfolio in Review

As of Q2 2026, Avidity Partners Management held 58 positions worth $624M, up 26% from $494M the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Avidity Partners Management deployed $40.1M of net new capital in Q2 2026, opening 13 new positions and adding to 11 existing holdings. Its largest new stake was Mobia Medical: 798,282 shares worth $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $8.33M trimmed.

  • Avidity Partners Management's largest Q2 2026 buy was Mobia Medical: 798,282 shares worth $10.7M.
  • Avidity Partners Management added most to CG Oncology in Q2 2026, an estimated $7.19M increase.
  • Avidity Partners Management's biggest Q2 2026 reduction was Teva Pharmaceuticals, cutting an estimated $8.33M.
  • Avidity Partners Management fully exited Centene in Q2 2026, selling an estimated $2.29M.
  • Avidity Partners Management's ten largest holdings make up 82% of its $624M portfolio in Q2 2026.
  • Avidity Partners Management opened 13 new positions and closed 13 in Q2 2026.
  • Avidity Partners Management's portfolio value rose 26% quarter-over-quarter to $624M.

Based on Avidity Partners Management's 13F filing for Q2 2026, filed 14 Aug 2026.